Media2024-01-23T11:12:29+01:00

Media

Press Releases

OncoOne at the 2023 AACR Annual Meeting
April 14, 2023

OncoOne Presents Preclinical Data Update from oxMIF-targeting Pipeline including ON203 and PreTarg-it ® ON-05 at the 2023 AACR Annual Meeting.

read more
OncoOne expands Scientific Advisory Board
September 07, 2022

To support our clinical studies, we are expanding our scientific advisory board with 3 top experts with outstanding expertise in MIF biology, inflammation, and immuno-oncology.

read more
OncoOne at the 2022 AACR Annual Meeting
April 08, 2022

OncoOne Presents Preclinical Proof of Concept Data for its Next-Generation oxMIF-targeted Monoclonal Antibody ON203 at the AACR Annual Meeting.

read more
OncoOne and GenScript ProBio Enter Agreement for the Manufacturing of Monoclonal Antibody Drugs Targeting oxMIF
Vienna, Austria and New Jersey, USA – November 17, 2021

read more
OncoOne establishes a U.S. subsidiary
September 13, 2021

OncoOne Appoints Brent Meadows as Chief Business Officer and establishes a U.S. subsidiary as base for strategic partnerships and business development activities.

read more
OncoOne Announces Initiation of IND‐Enabling Studies
June 10, 2021

OncoOne Announces Initiation of IND‐Enabling Studies for Lead Program Targeting Oxidized Macrophage Migration Inhibitory Factor and Secures EUR 1M to Explore Potential in Inflammatory Diseases.

read more
OncoOne – new Scientific Advisory Board
September 3, 2020

OncoOne is delighted to announce the formation of our new Scientific Advisory Board. This board will help shape and guide the strategy of OncoOne working closely with the leadership team.

read more
OncoOne Launches with EUR 13 Million Series
March 18, 2020

OncoOne Launches with EUR 13 Million Series A to Develop Multiple Drug Modalities for Unexplored Target.

read more

General News

Drug Target Review Issue 3 – Features our CEO
September, 2023

Our thanks to Drug Target Review for featuring an article by our CEO and Co-Founder, RandolfKerschbaumer, highlighting novel capabilities that address elusive therapeutic targets and their impact on the treatment paradigm for patients living with cancer. Download the article here to learn more about our innovative approach and recent developments behind our pipeline of therapeutic antibodies targeting oxMIF.

read more
First Article published on ON104
August, 2023

Thrilled to share a significant milestone: Our pioneering research paper on targeting oxidized macrophage migration inhibitory factor (oxMIF) to treat chronic inflammatory diseases, “The Newly Engineered Monoclonal Antibody ON104, Targeting Oxidized Macrophage Migration Inhibitory Factor (oxMIF), Ameliorates Clinical and Histopathological Signs of Collagen-Induced Arthritis,” is now published in the European Journal of Pharmacology, marking the start of an impactful series this year.

read more
OncoOne Celebrates its 5th Anniversary
June, 2023

It is hard to believe how time flies, and that OncoOne already celebrated its 5th anniversary last month. Together with our team, we took this opportunity to commemorate this amazing accomplishment!

read more
Job Promotion
Friedmund Bachmann to Vice President CMC

We are delighted to announce Friedmund Bachmann’s well-deserved promotion to the role of Vice President CMC at OncoOne, effective April 1, 2023!

read more
Job Promotion
Christine Landlinder-Schubert, Vice President Preclinical and Translational R&D

We are thrilled to announce the well-deserved promotion of Christine Landlinger-Schubert to the role of Vice President Preclinical and Translational R&D at OncoOne, effective April 1, 2023!

read more
First Article published on ON203 – our bioengineered second generation anti-oxMIF antibody for treatment of solid tumors

Preclinical Evaluation of ON203, A Novel Bioengineered mAb Targeting Oxidized Macrophage Migration Inhibitory Factor as an Anticancer Therapeutic” published in Molecular Cancer Therapeutics and selected by the editors as a First Disclosure.

read more
OncoOne Newsletter Q1/2023
April, 2023

OncoOne has had a successful start to 2023, with the lead oxMIF mAb for solid tumors, ON203, being featured in the American Association for Cancer Research’s journal Molecular Cancer Therapeutics. The summary of ON203’s design and preclinical experiments has been published online in conjunction with the AACR Annual Meeting 2023 in Orlando and will be MCT’s feature article in May

Job Promotion
Maroua Ferhat, Senior Scientist

We are thrilled to announce that Maroua Ferhat, PhD has been awarded the promotion to Senior Scientist effective March 1, 2023

read more
Job Promotion
Maria Reitzinger to Head of Finance and Administration

We are pleased to announce the promotion of Maria Reitzinger to Head of Finance and Administration, effective March 1, 2023.

read more
OncoOne Newsletter Q4/2022
January, 2023

In the fourth quarter of 2022, we traveled around the world sharing our message about the potential of oxMIF as an immuno-oncology and inflammation target. With our Series B raise underway and completion of several value-building projects we value this opportunity to update you on OncoOne’s progress.

Seal of Recognition Award
December 19th, 2022

We are happy to share that our CEO, Randolf Kerschbaumer has been awarded the Seal of Recognition at the Healthcare 2.0 Conference in acknowledgement of his exceptional leadership at OncoOne. Congratulations, Randolf!

New Review Article on oxMIF
September, 2022

Our CSO, Michael Thiele has published the review article “OxMIF: a druggable isoform of macrophage migration inhibitory factor in cancer and inflammatory diseases” in the Journal for Immunotherapy of Cancer. With support from OncoOne’s new SAB members, Dr. Seamas Donnelly and Dr. Robert Mitchell, Michael highlights the potential of oxMIF as an attractive therapeutic target capable of overcoming the challenges posed by the Macrophage Migration Inhibitory Factor (MIF)

OncoOne Newsletter Q3/2022
September, 2022

As summer draws to a close, we at OncoOne are preparing for upcoming major industry conferences, continuing our fundraising efforts with potential partners and interested investors, and celebrating our recent corporate milestones.

OncoOne Newsletter Q2/2022
July, 2022

Another successful quarter in the books at OncoOne. Get more information about the Second Quarter 2022 Highlights and upcoming events of OncoOne.

OncoOne Newsletter Q1/2022
April, 2022

Et voilà: our first, quarterly newsletter including key achievements and upcoming events of OncoOne.

First academic thesis at OncoOne
May, 2021

The first academic thesis at OncoOne has been completed. Our team member, Gregor Rossmüller, conducted and successfully completed his master’s thesis at OncoOne. He graduated at the University of Natural Resources and Applied Life Sciences (BOKU), Vienna.

OncoOne moved laboratory & office
April, 2020

We moved our laboratory and office activities to the Vienna BioCenter. The head office remains in Klosterneuburg.

CEO at Golden Ribbon Run
May, 2019

Our CEO, Randolf Kerschbaumer represented OncoOne at this year’s Golden Ribbon Run in Klosterneuburg. The Golden Ribbon Run is all about drawing attention to the joint fight against childhood cancer and all the money raised will be donated to Kinderkrebshilfe, the representative for the interests of children and adolescents suffering from cancer and their families, in Austria.

OncoOne met Dr. Petra Buhoslav
March, 2019

We presented our startup, OncoOne to state councilor, Dr. Petra Bohuslav. We thank Dr. Bohuslav and the Accent Incubator for their interest in our research projects and for the great discussion!

OncoOne received a grant
November, 2018

OncoOne received a grant from the leading national funding agency for industrial research and development in Austria, The Austrian Research Promotion Agency (FFG).

OncoOne opened labs in Vienna
October, 2018

OncoOne opened our labs at the University of Natural Resources and Life Sciences, Vienna.

OncoOne received pre-seed funding
August, 2018

OncoOne received pre-seed funding from the Austria Wirtschaftsservice Gesellschaft (AWS).

OncoOne participates the incubator program
August, 2018

OncoOne was accepted by the Accent Incubator board to participate in the incubator program of Lower Austria.

The birthday of OncoOne
June, 2018

OncoOne was founded by Randolf Kerschbaumer, Michael Thiele and Alexander Schinagl.

New Hires

Stephanie Spach, MSc
July, 2023

We are delighted to welcome Stephanie Spach, MSc, as the newest member of the OncoOne team, joining us on July 1st. Stephanie will be a valuable addition as a Research Associate in our Biology Team.

Dr. Sara Sajko
September, 2021

OncoOne welcomed our new team member Dr. Sara Sajko, Scientist who will support our Biotechnology Group.

Dr. Christine Landlinger-Schubert
August, 2021

OncoOne welcomed Dr. Christine Landlinger-Schubert, Director Preclinical Development & Project Lead Inflammation who will oversee and manage non-clinical studies for our new biotherapeutics.

Friedmund Bachmann
April, 2021

OncoOne welcomed Friedmund Bachmann, our new Director of CMC Biologics, who will support us in manufacturing, analytics and quality control efforts.

Alejandro Puchol Tarazona
March, 2021

OncoOne welcomed our new Scientist, Alejandro Puchol Tarazona to the Biotechnology Group. Alejandro will support the protein engineering activities and protein production.

Verena Höld
September, 2020

We welcomed our new Research Associate, Verena Höld to our team. Verena will support our bioengineering and cell biology activities.

Maria Reitzinger
June, 2020

We welcomed our management assistant, Maria Reitzinger to the OncoOne team. Maria will support our CEO in all organisational and administrative tasks.

Julia Mayer
December, 2019

We welcomed our new Research Associate, Julia Mayer to the OncoOne team. Julia will support our cell biology activities.

Irina Mirkina
October, 2019

We welcomed Irina Mirkina to our team. Irina (Senior Scientist) will support bioengineering and cell biology activities.

.

Gregor Rossmüller
December, 2018

We would like to welcome Gregor Rossmüller to our team. Gregor will support us as Research Associate.

Scientific Conferences

JP Morgan, San Francisco
Januar 8-11, 2024

Our CEO, Randolf Kerschbaumer, and CSO, Michael Thiele, are looking forward to connecting with the biotech, pharma, VC, and investor community at JP Morgan Healthcare Conference! Please feel free to reach out.

TRP, Berlin
December 5-7, 2023

OncoOne invites you to join us at the Targeted Radiopharmaceuticals Summit Europe in Berlin from December 5 to 7. Our VP CMC Friedmund Bachmann will be sharing the latest insights on OncoOne’s innovative PreTarg-it® platform on Tuesday, December 6, 13:00 CET at TRP23. Explore how our Modular PreTarg-it® Platform is advancing RIT for challenging cancers, ultimately improving therapeutic indexes. If you’re interested in connecting with Friedmund and learning more about the PreTarg-it® platform, please reach out.

PEGS Europe, Lisbon
Ocotober 13-16, 2023

Join OncoOne at PEGS Europe in Lisbon from November 14 to 16. Our CTO Alexander Schinagl will be presenting the latest insights on OncoOne’s PreTarg-it® platform on Tuesday, November 14, at #PEGS23. Discover how our Modular PreTargit Platform enhances RIT for challenging cancers, improving therapeutic indexes. Let’s connect and exchange ideas after his presentation!

Festival of Biologics, Basel
October 10-12, 2023

Will you be joining us at the Festival of Biologics in Basel next week? Don’t miss the presentation by our CSO, Michael Thiele, titled “Antibody ON104: Alleviating Inflammation by Neutralizing Key Pathological Functions of oxMIF.” Also, be sure to visit our poster #76, where our Senior Scientist Maroua Ferhat will be showcasing ON104’s efficacy in a mouse arthritis model. It’s an excellent opportunity to delve into the promising potential of our leading candidate, the anti-oxMIF antibody ON104, as a an innovative treatment for autoimmune diseases.”

EANM, Vienna
September 9-13, 2023

We are pleased to announce that our VP of CMC, Friedmund Bachmann, and Scientist Alejandro Puchol will be presenting at the upcoming Congress of the European Association of Nuclear Medicine (EANM23) in Vienna, taking place from September 9-13, 2023.

1. “Pretargeted Radioimmunotherapy with an Anti-oxMIF/HSG Bispecific Antibody Demonstrates Efficacy in Murine Models of Cancer.”
2. “Preclinical PET imaging with 89Zr-labelled oxMIF-specific antibody – ON102 – delineates subcutaneous tumors in colorectal murine models.”

60TH ERA Congress, Milan
June 15-18, 2023

We are proud to announce that Christine Landlinger-Schubert, our VP of Preclinical and Translational R&D, will be delivering a Focused Oral presentation at the ERA Congress held from June 15-18 in Milan, Italy. Christine’s presentation titled “ON104: A novel bioengineered antibody targeting oxidized Macrophage Migration Inhibitory Factor (oxMIF) ameliorates experimental Glomerulonephritis” is not to be missed.

.

PEGS 2023, Boston
May 15-19, 2023

Join our CTO Alexander Schinagl at PEGS Boston. OncoOne is excited to present our latest research on “Pretargeted Radioimmunotherapy with an Anti-oxMIF/HSG Bispecific Antibody Demonstrates Efficacy in Murine Models of Cancer” at PEGS23. The study highlights the potential of our innovative PreTarg-it® platform combining a bispecific antibody and radioligand for targeting and treating solid tumors.

.

AAI Annual Meeting 2023, Washington
May 11-15, 2023

OncoOne is excited to announce that our CTO, Alexander Schinagl, and Senior Scientist, Maroua Ferhat, will be attending the American Association of Immunologists IMMUNOLOGY2023™ #AAI2023 in Washington DC. During the conference, Maroua will be presenting our latest research on “ON104, a novel antibody targeting oxidized macrophage migration inhibitory factor (oxMIF) shows efficacy in preclinical models of chronic inflammation“.

AACR Annual Meeting 2023, Orlando
April 14-19, 2023

Meet with our CTO Alexander Schinagl and CBO Brent Meadows at our two posters entitled: Abstract #2974 “Targeting the oxidized form of macrophage migration inhibitory factor (oxMIF) with antibody ON203 activates the tumor microenvironment” and Abstract #585 “Pretargeted radioimmunotherapy with a novel anti-oxMIF/HSG bispecific antibody and a 177Lu-loaded HSG radioligand results in significant tumorregression in murine models of cancer”.

Immuno UK 2023, London
March 28-29, 2023

Participating in the Immuno 2023 in London from March 28 – 29? Be sure to attend the presentation by our CSO, Michael Thiele entitled “Targeting oxMIF in autoimmune diseases” on March 28 from 11:10 – 11:35 am GMT. Participants will have the opportunity to learn more about the promising potential of our novel bioengineered monoclonal antibody ON104 targeting oxMIF as a novel treatment approach for autoimmune diseases and meet with Michael and our Director Precinical Christine Landlinger-Schubert.

7th Annual MarketsandMarkets Next-Gen Immuno-Oncology Conference, London, UK
March 9-10, 2023

Meet our Senior Scientist, Barbara Maurer at 7th Annual MarketsandMarkets Next-Gen Immuno-Oncology Conference in London from March 9 – 10 and join Barbara for her talk entitled: “ON203 – A new antibody targeting the oxidized form of macrophage migration inhibitory factor oxMIF exerts antitumorigenic activity and modulates the tumor microenvironment” on March 10, at  2:15 – 2:45 pm GMT

18th Annual Congress of the European Crohn’s and Colitis Organisation, Copenhagen
March 1-4, 2023

Meet with our Scientist Maroua Ferhat for the ECCO 2023 held in Copenhagen from March 1 – 4, where she will lead a poster presentation on our oxMIF-targeting monoclonal antibody, ON104, which shows efficacy in two distinct preclinical models of experimental colitis.

Targeted Radiopharmaceuticals Summit Europe, Amsterdam
December 6-8, 2022

Join our Director CMC Biologics, Friedmund Bachmann at the 4th TRPEurope Summit in Amsterdam. Conference participants will have the opportunity to meet Friedmund during a presentation examining ON102, our proprietary radioimmunoconjugate designed to provide a non-invasive approach for diagnostic applications.

European Multispecific Antibody Congress, Amsterdam
February 22-23, 2023

Meet Alexander Schinagl, our CTO at the European Multispecific Antibody Congress next week in Amsterdam from February 22–23, 2023. On the 22nd, he will present data on our modular PreTarg-it® platform which utilizes bispecific antibodies, designed for optimal tumor penetration and enhanced payload delivery.

14th Annual PEGS Europe, Barcelona
November 14–16, 2022

Meet Irina Mirkina (Principal Scientist), Alejandro Puchol (Scientist) & Gregor Rossmüller (Doctoral Student) at PEGS Europe in Barcelona, Spain, where Alejandro will present a poster on the preclinical efficacy of novel anti-oxMIF/HSG bispecific antibody for pretargeted radioimmunotherapy.

ACR Convergence 2022,
Philadelphia PA
November 10–14, 2022

Our Director Preclinical Development & Project Lead Inflammation Christine Landlinger will attend the ACR Convergence and give a virtual poster presentation on our oxMIF targeting antibody ON104 as a novel treatment approach for Rheumatoid Arthritis.

SITC, Boston MA
November 8–12, 2022

Meet our CEO, Randolf Kerschbaumer at the SITC 37th Annual Meeting in Boston MA, USA, where he will present a poster on our novel oxMIF targeting antibody ON203 and its antitumorigenic activity.

Festival of Biologics, Basel
November 2–4, 2022

Our Scientist Maroua Ferhat will attend the Festival of Biologics in Basel, Switzerland. Be sure to visit her talk on ON104, our Novel Bioengineered Monoclonal Antibody Targeting Oxidized Macrophage Migration Inhibitory Factor (oxMIF) in autoimmune disorders.

ENA 2022
October 26–28, 2022

Meet our CTO, Alexander Schinagl at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium, October 26–28, in Barcelona. Alexander will present a poster (#347) on antitumorigenic activities of ON203 in preclinical models.

Annual Immuno-Oncology Summit, 2022
October 12–14, 2022

Our CSO, Michael Thiele will attend the 10th Annual Immuno-Oncology Summit in Boston. Michael will give a talk on immunomodulatory activities of our clinical candidate anti-oxMIF antibody ON203 in patient-derived colorectal cancer tumoroids.

CICON 2022 & Macrophage-directed Therapies Summit, 2022
September 28 – October 01, 2022 & October 4 – 6, 2022

Our CEO Randolf Kerschbaumer will attend the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference (CICON) in New York AND the 4th Macrophage-directed Therapies Summit in Boston. Randolf was invited to present at both meetings to share data on the antitumorigenic and TME-modifying potential of our clinical anti-oxMIF antibody ON203.

World Bispecific Summit, 2022
September 20–22, 2022

Meet our CTO, Alexander Schinagl at the 13th World Bispecific Summit in Boston, US. Alexander will present data on our modular PreTarg-it® platform  which utilizes bispecific antibodies for optimized biodelivery of payloads.

World Conference of Lung Cancer, 2022
August 6–9, 2022

Meet our Director Preclinical Development, Christine Landlinger at the WCLC in Vienna, Austria. Be sure to visit Christine’s e-poster on August 8 to learn more about our clinical candidate for the treatment of malignant solid tumors (e-poster EP08.01-015 – Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Anti-oxMIF Antibody ON203 in Malignant Solid Tumors).

ESMO GI
June 29–July 2, 2022

Our Senior Scientist Barbara Maurer will attend the ESMO World Congress on Gastrointestinal Cancer in Barcelona, Spain. Barbara will present data demonstrating antitumorigenic activity and TME modulation of ON203 in patient-derived colorectal cancer tumoroids.

Theranostics World Congress
June 24–26, 2022

Our Director CMC Biologics, Friedmund Bachmann will attend the 6th Theranostics World Congress in Wiesbaden, Germany. He will present a poster on ON102, our diagnostic radioimmunoconjugate targeting oxMIF.

EACR 2022
June 20–23, 2022

Meet our Director Preclinical Development, Christine Landlinger & Barbara Maurer, Senior Scientist at the EACR 2022 in Seville, Spain. Be sure to visit Barbara’s poster on ON203 to learn more about our clinical candidate for solid tumor indications.

World Congress on Inflammation
June 5–8, 2022

Meet our Director Preclinical Development & Project Lead Inflammation, Christine Landlinger & Maroua Ferhat, Research Scientist at the WCI22 in Rome. Be sure to visit Christine’s talk on our inflammation candidate ON104 to learn more.

ASCO 2022
June 3–7, 2022

Meet our CBO, Brent Meadows at the ASCO 2022 in Chicago to learn more about OncoOne’s novel therapies for the treatment of solid tumors and autoimmune diseases.

Immuno-Oncology Summit Europe
May 23–25, 2022

Our CSO, Michael Thiele will give a podium presentation entitled “Novel Therapeutic Antibodies Targeting Oxidized Macrophage Migration Inhibitory Factor (oxMIF)” in the program “Targeting the Tumour Microenvironment” at the Immuno-Oncology Summit Europe.

PEGS Boston: The Essential Protein Engineering & Cell Therapy Summit
May 2–6, 2022

Our CSO, Michael Thiele will be leading a session entitled “A New Immunotherapy Target: Co-Development of a Therapeutic Antibody and a Radioimmune Diagnostic Targeting Oxidized Macrophage Migration Inhibitory Factor (oxMIF)” at the PEGS, Boston, US.

12th Clinical Biomarker & CDx Summit Europe
April 27–28, 2022

OncoOne’s CEO Randolf Kerschbaumer will give a talk on “oxMIF as a novel biomarker and immuno-oncology therapeutic target for precision medicine”, at the 12th Clinical Biomarker & CDx Summit Europe; April 27–28, London, UK.

AACR Annual Meeting 2022
April 08–13, 2022

OncoOne will present its latest development for the treatment of solid tumors and lead candidate ON203 live at the AACR in New Orleans. Visit us at our poster presentation on Sunday, April 10th in Exhibit Halls D-H, Section 21, Poster # 313, and meet OncoOne’s CTO, Alexander Schinagl, CBO, Brent Meadows, and CEO, Randolf Kerschbaumer, in person.

Cambridge Healthtech Institute’s 9th Annual Immuno-Oncology Summit, Boston
October 4–6th, 2021

Meet our new CBO, Brent Meadows, at CHI’s 9th Annual Immuno-Oncology Summit in Boston to learn more about OncoOne’s pipeline of novel, anti-cancer therapies for the treatment of solid tumors and inflammation. Please visit OncoOne at poster #6 entitled “Harnessing oxidized macrophage migration inhibitory factor (oxMIF) as a druggable isoform of MIF for targeted anticancer therapies”.

To view the virtual poster presentation by OncoOne’s CSO, Michael Thiele, please click here.

PEGS summit Europe
November 12–16, 2018

Meet OncoOne’s Heads of External and Internal Research, Michael Thiele and Alexander Schinagl at the Protein & Antibody Engineering Summit in Lisbon, Portugal.

Partnering Conferences

BIO EUROPE 2023, Munich
October 6-8, 2023

OncoOne’s leadership team, including Randolf Kerschbaumer, CEO, Alexander Schinagl, CTO, and Christine Landlinger-Schubert, VP Preclinical and Translational R&D, will be present at BioEurope from November 6-8 in Munich, Germany. Feel free to reach out and connect with us to explore OncoOne’s innovative antibody pipeline targeting oxMIF and discover our proprietary PreTarg-it® platform.

BIO International Convention 2023, Boston
June 5-8, 2023

OncoOne’s CEO, Randolf Kerschbaumer, will be attending the BIO International Convention in Boston from June 5-8! With a projected 44,000+ meetings scheduled over four days, we can’t wait to connect with like-minded companies who share our passion for science.

Bio€quity 2023, Dublin
May 14-16, 2023

OncoOne’s CSO, Michael Thiele, will be attending #BIOEQUITY in Dublin from May 14-16! This is a great opportunity to connect with us and discuss potential collaborations to advance our innovative research in oncology and inflammation therapies to the clinic.

BIO Asia Partnering Forum, Singapore
April 26-27, 2023

Delighted to announce that OncoOne’s CEO, Randolf Kerschbaumer, will be attending BIO Asia Partnering Forum #ASIABIO, held in Singapore April 26-27! Join us as he presents our latest developments in our oxMIF targeted pipeline for cancer and inflammation.

BIO Europe Spring 2023, Basel, CH
March 20–22, 2023

Meet our CEO, Randolf Kerschbaumer, at the BIO-Europe Spring 2023 to learn more about OncoOne’s novel therapies for the treatment of solid tumors and chronic inflammatory diseases. Reserve a spot using the partneringONE® tool to speak with our management team about the recent developments of our corporate agenda and how we are preparing our oxMIF-targeted candidates ON104 and ON203 for clinical evaluation.

16th Annual European Life Sciences CEO Forum, Zurich, CH
March 1-2, 2023

OnoOne’s CEO, Randolf Kerschbaumer will be traveling to Zurich for the 16th Annual European Life Sciences CEO Forum, held on March 1-3. We look forward to connecting in person and discussing why we believe oxMIF, discovered by our founders, is a promising new target in immunology and oncology capable of unlocking the key to drugging MIF, a critical driver in innate & adaptive immunity.

J.P. Morgan Conference, San Francisco
January 9–12, 2023

SavetheDate: OncoOne’s CEO, Randolf Kerschbaumer, and CBO, Brent Meadows will be attending the 41st annual J.P. Morgan Conference in San Francisco, January 9-12, 2023. Reserve a spot to speak with our management team about the recent developments of our corporate agenda and how we are preparing our oxMIF-targeted candidates ON104 and ON203 for clinical evaluation.

BIO Europe
October 24–26, 2022

Meet OncoOne’s CEO, Randolf Kerschbaumer and CBO, Brent Meadows at the BIO Europe in Leipzig, Germany!

BIO Asia-Taiwan
July 27–31, 2022

OncoOne’s CBO, Brent Meadows attended the BIO Asia-Taiwan to discuss our groundbreaking approach to targeting MIF.

BIO2022
June 13–16, 2022

OncoOne’s CEO, Randolf Kerschbaumer will be present at the BIO2022. Randolf will give a corporate presentation on June 15 at 4:45 PM PDT on our innovative oxMIF-targeting pipeline in oncology & immunology.

BIO Europe Spring digital event
March 28–31, 2022

Meet our CBO, Brent Meadows, CEO, Randolf Kerschbaumer, and CSO, Michael Thiele, at the digital BIO-Europe Spring 2022 to learn more about OncoOne’s novel therapies for the treatment of solid tumors and inflammatory/autoimmune diseases.

BIO-Europe Spring Digital Event
March 22–25, 2021

Meet our CEO, Randolf Kerschbaumer and CSO, Michael Thiele at the digital BIO-Europe Spring to learn more about OncoOne’s mission to develop novel, anti-cancer therapies for the treatment of solid tumors.

BIO CEO & Investors Conference, NYC
February 14th, 2022

Our CEO Randolf Kerschbaumer and our CBO Brent Meadows will attend in person at the hybrid 2022 BIO CEO & Investor Conference in NYC.
Randolf will present OncoOne’s corporate highlights and progress live at 10am EST on February 14th, 2022.

BIO-Europe Spring Digital Event
March 23–27, 2020

OncoOne’s CEO, Randolf Kerschbaumer and CSO, Michael Thiele will participate in the BIO-Europe Spring digital event.

BIO-Europe
November 11–13, 2019

OncoOne’s CEO, Randolf Kerschbaumer and COO, Michael Thiele will attend BIO-Europe in Hamburg, Germany.

3rd Drug Discovery Nexus Summit
May 23–24, 2019

Meet OncoOne’s CEO, Randolf Kerschbaumer at the 3rd Drug Discovery Nexus Summit in Munich, Germany.

BIO-Europe Spring
March 25–27, 2019

Meet OncoOne’s CEO, Randolf Kerschbaumer at the BIO-Europe Spring in Vienna, Austria.

Oncology Strategy Meeting Europe
March 13, 2019

Meet OncoOne’s CEO, Randolf Kerschbaumer at the Oncology Strategy Meeting Europe 2019 in Munich, Germany.

Publications

    • Ferhat, M. et al. (2023) ‘The newly engineered monoclonal antibody ON104, targeting the oxidized Macrophage Migration Inhibitory Factor (oxMIF), ameliorates clinical and histopathological signs of collagen-induced arthritis’, European Journal of Pharmacology, (956). doi.org/10.1016/j.ejphar.2023.175997
    • Rossmueller, G. et al. (2023) ‘Preclinical Evaluation of ON203, A Novel Bioengineered mAb Targeting Oxidized Macrophage Migration Inhibitory Factor as an Anticancer Therapeutic’, Molecular Cancer Therapeutics, pp. OF1–OF15. doi: 10.1158/1535-7163.MCT-22-0676.
    • Thiele, M., Donnelly, S. C. and Mitchell, R. A. (2022) ‘OxMIF: a druggable isoform of macrophage migration inhibitory factor in cancer and inflammatory diseases’, Journal for ImmunoTherapy of Cancer, p. e005475. doi: 10.1136/jitc-2022-005475.
    • Skeens, E. et al. (2022) ‘Redox-dependent structure and dynamics of macrophage migration inhibitory factor reveal sites of latent allostery’, Structure, 0(0). doi: 10.1016/J.STR.2022.03.007.
    • Höllriegl, W. et al. (2018) ‘Pharmacokinetics, disease-modifying activity, and safety of an experimental therapeutic targeting an immunological isoform of macrophage migration inhibitory factor, in rat glomerulonephritis’, European Journal of Pharmacology, 820(December 2017), pp. 206–216. doi: 10.1016/j.ejphar.2017.12.040.
    • Schinagl, A. et al. (2018) ‘Role of the Cysteine 81 Residue of Macrophage Migration Inhibitory Factor as a Molecular Redox Switch’, Biochemistry, 57(9), pp. 1523–1532. doi: 10.1021/acs.biochem.7b01156.
    • Schinagl, A. et al. (2016) ‘Oxidized macrophage migration inhibitory factor is a potential new tissue marker and drug target in cancer’, Oncotarget, 7(45). doi: 10.18632/oncotarget.11970.
    • Mahalingam, D. et al. (2015) ‘First-in-human, phase I study assessing imalumab (Bax69), a first-in-class anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody in advanced solid tumors.’, Journal of Clinical Oncology, 33(15_suppl), p. 2518. doi: 10.1200/jco.2015.33.15_suppl.2518.
    • Thiele, M. et al. (2015) ‘Selective Targeting of a Disease-Related Conformational Isoform of Macrophage Migration Inhibitory Factor Ameliorates Inflammatory Conditions’, The Journal of Immunology, 195(5), pp. 2343–2352. doi: 10.4049/jimmunol.1500572.
    • Hussain, F. et al. (2013) ‘Human Anti-Macrophage Migration Inhibitory Factor Antibodies Inhibit Growth of Human Prostate Cancer Cells In Vitro and In Vivo’, Molecular Cancer Therapeutics, 12(7), pp. 1223–1234. doi: 10.1158/1535-7163.MCT-12-0988.
    • Kerschbaumer, R. J. et al. (2012) ‘Neutralization of macrophage migration inhibitory factor (MIF) by fully human antibodies correlates with their specificity for the β-sheet structure of MIF’, Journal of Biological Chemistry, 287(10), pp. 7446–7455. doi: 10.1074/jbc.M111.329664.
Go to Top